Harbor Advisors LLC held its stake in Astrazeneca PLC (NYSE:AZN) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,000 shares of the company’s stock at the close of the second quarter. Harbor Advisors LLC’s holdings in Astrazeneca PLC were worth $409,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Meeder Asset Management Inc. purchased a new stake in shares of Astrazeneca PLC in the second quarter valued at about $105,000. Salem Investment Counselors Inc. purchased a new position in shares of Astrazeneca PLC during the 1st quarter worth approximately $107,000. Tower Research Capital LLC TRC increased its stake in shares of Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after purchasing an additional 3,782 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Astrazeneca PLC by 27.1% during the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after purchasing an additional 964 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. increased its stake in shares of Astrazeneca PLC by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after purchasing an additional 1,769 shares in the last quarter. Institutional investors own 14.17% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/04/astrazeneca-plc-azn-position-held-by-harbor-advisors-llc.html.

A number of equities research analysts have commented on AZN shares. Zacks Investment Research cut Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. Natixis raised Astrazeneca PLC from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. BidaskClub cut Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Argus reissued a “buy” rating and issued a $35.00 price target on shares of Astrazeneca PLC in a report on Friday, September 1st. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.20.

Shares of Astrazeneca PLC (AZN) traded up 0.20% during mid-day trading on Wednesday, hitting $34.33. The stock had a trading volume of 470,510 shares. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. The company has a 50-day moving average of $31.44 and a 200 day moving average of $32.08. The firm has a market cap of $86.92 billion, a price-to-earnings ratio of 22.52 and a beta of 0.76.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the firm earned $0.83 earnings per share. The business’s revenue for the quarter was down 9.9% on a year-over-year basis. On average, equities research analysts forecast that Astrazeneca PLC will post $1.91 earnings per share for the current year.

The company also recently declared a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were paid a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.